A common anaesthetic has been quarantined across Australia after three hospital patients in South Australia contracted a blood infection.
The Therapeutic Goods Administration yesterday quarantined two batches of propofol manufactured by Claris Lifesciences due to potential contamination with the bacteria Ralstonia pickettii.
TGA spokeswoman Kay McNiece said samples were being tested to determine the cause of the possible contamination.
‘‘This follows the discovery of three patients at two different hospitals in South Australia who have developed sepsis after propofol was administered to them in the course of their hospitalisation during the period April 13-27,’’ she said.
‘‘The TGA has held two teleconferences with state and territory chief health officers to alert them to this potential contamination and has ensured that all hospitals, doctors, anaesthetists and other health care professions who may use the product are aware of the health concerns and quarantine procedures.’’
The short-acting general anaesthetic is commonly used on adults and children over three.
Royal Melbourne Hospital spokeswoman Melea Tarabay said the recall would not delay operations at the hospital.
"We do use that drug but from a different company and that company's not affected by the recall of the drug."
The Alfred spokeswoman Hannah Chipp said the hospital had not received any of the affected batches.